Although prophylactic and/or therapeutic drugs are being developed at an unprecedented pace, it is still unknown when the epidemic will be under effective control all over the world. One of the most crucial reasons is that a larger number of prevalent mutations and deletions in S glycoprotein have emerged since the start of the outbreak and this rapid viral evolution could either facilitate transmissibility, or lead to reduction in protective efficacy of vaccines and mAbs . Typically, SARS-CoV-2 Beta (B.1.351/501Y.V2) variant, emerging in late 2020 in Eastern Cape, South Africa (SA), contains 9 S protein mutations including three mutations (K417N, E484K, N501Y) in RBD, a cluster of NTD mutations (e.g., 242-244del & R246I) and so on .